Theratechnologies Inc
TSX:TH

Watchlist Manager
Theratechnologies Inc Logo
Theratechnologies Inc
TSX:TH
Watchlist
Price: 2.6 CAD 0.78% Market Closed
Market Cap: 119.5m CAD
Have any thoughts about
Theratechnologies Inc?
Write Note

EV/EBITDA
Enterprise Value to EBITDA

6.8
Current
-6.4
Median
4.2
Industry
Higher than median
Higher than industry value

Enterprise Value to EBITDA (EV/EBITDA) ratio is a valuation multiple that compares the value of a company, debt included, to the company’s cash earnings less non-cash expenses. EBITDA can be misleading at times, especially for companies that are highly capital intensive.

EV/EBITDA
6.8
=
Enterprise Value
116.1m CAD
/
EBITDA
11.9m USD
All Countries
Close
Market Cap EV/EBITDA
CA
Theratechnologies Inc
TSX:TH
119.5m CAD 6.8
FR
Pharnext SCA
OTC:PNEXF
6T USD -220 094.3
US
Abbvie Inc
NYSE:ABBV
316.5B USD 15.5
US
Amgen Inc
NASDAQ:AMGN
141.2B USD 16
US
Gilead Sciences Inc
NASDAQ:GILD
117.1B USD 10.3
US
Vertex Pharmaceuticals Inc
NASDAQ:VRTX
105.3B USD 21.7
US
Epizyme Inc
F:EPE
94.1B EUR -513.4
AU
CSL Ltd
ASX:CSL
135.7B AUD 19.8
US
Regeneron Pharmaceuticals Inc
NASDAQ:REGN
78.2B USD 15.3
US
Seagen Inc
F:SGT
39.3B EUR -58.6
NL
argenx SE
XBRU:ARGX
36B EUR -109.3
EBITDA Growth EV/EBITDA to Growth
CA
Theratechnologies Inc
TSX:TH
Average EV/EBITDA: 15
6.8
N/A N/A
FR
Pharnext SCA
OTC:PNEXF
Negative Multiple: -220 094.3 N/A N/A
US
Abbvie Inc
NYSE:ABBV
15.5
29%
0.5
US
Amgen Inc
NASDAQ:AMGN
16
62%
0.3
US
Gilead Sciences Inc
NASDAQ:GILD
10.3
16%
0.6
US
Vertex Pharmaceuticals Inc
NASDAQ:VRTX
21.7
43%
0.5
US
E
Epizyme Inc
F:EPE
Negative Multiple: -513.4 N/A N/A
AU
CSL Ltd
ASX:CSL
19.8
42%
0.5
US
Regeneron Pharmaceuticals Inc
NASDAQ:REGN
15.3
35%
0.4
US
S
Seagen Inc
F:SGT
Negative Multiple: -58.6 N/A N/A
NL
argenx SE
XBRU:ARGX
Negative Multiple: -109.3 N/A N/A

EV/EBITDA Forward Multiples

Forward EV/EBITDA multiple is a version of the EV/EBITDA ratio that uses forecasted EBITDA for the EV/EBITDA calculation. 1-Year, 2-Years, and 3-Years forwards use EBITDA forecasts for 1, 2, and 3 years ahead, respectively.

1-Year Forward
EV/EBITDA
4.3
2-Years Forward
EV/EBITDA
4.2
3-Years Forward
EV/EBITDA
2.9

See Also

Discover More